---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-216147"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:04:51.978572+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines Q2 net loss $61.2M; advances first two RAS(ON) inhibitors into clinic

## Summary
- Net loss $61.2M in Q2 2022 vs $44.3M in Q2 2021; revenue from Sanofi collab $9.1M.
- Cash, equivalents and securities $461.4M at June 30, 2022; July public offering raised $264.5M gross.
- Updated FY 2022 GAAP net loss guidance to $260-280M; stock-based comp $30-35M.
- First patient dosed in Phase 1/1b trial of RAS(ON) inhibitor RMC-6236; site activation for RMC-6291 underway.
- Appointed Lorence Kim (ex-Moderna, Goldman Sachs) and Sushil Patel (ex-Genentech) to Board of Directors.

## SEC filing metadata
- accession: 0001193125-22-216147
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000119312522216147/0001193125-22-216147-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000119312522216147/d348230d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-216147
- JSON: https://secwatch.observer/filing/0001193125-22-216147.json
- Plain text: https://secwatch.observer/filing/0001193125-22-216147.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.